Edelman G, Rodon J, Lager J, et al. Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors. Oncologist. 2018;23(4):401-e38. doi:10.1634/theoncologist.2017-0691
Wang Z, Fraley C, Mezo AR. Discovery and structure-activity relationships of small molecules that block the human immunoglobulin G-human neonatal Fc receptor (hIgG-hFcRn) protein-protein interaction. Bioorg Med Chem Lett. 2013;23(5):1253-6. doi:10.1016/j.bmcl.2013.01.014